Skip Navigation


eCAM Advance Access originally published online on September 14, 2006
eCAM 2007 4(1):43-50; doi:10.1093/ecam/nel051
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
4/1/43    most recent
nel051v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nakhai, L. A.
Right arrow Articles by Abdollahi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakhai, L. A.
Right arrow Articles by Abdollahi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease

Leila Ashtaral Nakhai1, Azadeh Mohammadirad1, Narges Yasa2, Bagher Minaie3, Shekoufeh Nikfar1, Ghazal Ghazanfari1, Mohammad Jafar Zamani1, Gholamreza Dehghan1, Hamidreza Jamshidi1, Vahid Shetab Boushehri1, Reza Khorasani1 and Mohammad Abdollahi1

1Laboratory of Toxicology, Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, 2Laboratory of Pharmacognosy, Faculty of Pharmacy and Medicinal Plants Research Center and 3Laboratory of Histopathology, School of Medicine, Tehran University of Medical Sciences Tehran, Iran


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Inflammatory bowel disease (IBD) is a chronic condition of the intestine with unknown etiology involving multiple immune, genetic and environmental factors. We were interested to examine the effect of total extract from Zataria multiflora Boiss, a folk medicinal plant on prevention and treatment of experimental IBD. Z. multiflora was administered (400, 600, 900 p.p.m.) through drinking water to IBD mice induced by intrarectal administration of acetic acid. Prednisolone was used as the standard drug for comparison. Biochemical, macroscopic and microscopic examinations of colon were performed. Biochemical evaluation of inflamed colon was done using assay of myeloperoxidase (MPO) activity and thiobarbituric acid reactive substances (TBARS) concentration as indicators of free radical activity and cell lipid peroxidation. The activity of MPO and lipid peroxidation products (TBARS) increased in acetic acid-treated groups while recovered by pretreatment of animals with Z. multiflora (400–900 p.p.m.) and prednisolone. Z. multiflora (600 and 900 p.p.m.) and prednisolone-treated groups showed significantly lower score values of macroscopic and microscopic characters when compared with the acetic acid-treated group. The beneficial effect of Z. multiflora (900 p.p.m.) was comparable with that of prednisolone. The antioxidant, antimicrobial and anti-inflammatory potentials of Z. multiflora might be the mechanisms by which this herbal extract protects animals against experimentally induced IBD. Proper clinical investigation should be carried out to confirm the activity in human.

Keywords: inflammatory bowel disease – antioxidant – cells lipid peroxidation – myeloperoxidase – rat – Zataria


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Conclusion
 References
 
Inflammatory bowel disease (IBD) comprises those conditions characterized by a tendency for chronic or relapsing immune activation and inflammation within the gastrointestinal tract. The intestinal inflammation is histologically characterized by infiltration of polymorphonuclear leukocytes, monocytes and macrophages. They are activated by various mediators including prostaglandins, leukotrienes, platelet-activating factor and cytokines to synthesize and liberate reactive oxygen metabolites (1,2).

The balance between the production of free radical and antioxidant defense in the body has important health implications: if there are too many free radicals or too few antioxidant for protection, a condition of oxidative stress develops, which may cause chronic and pretreatment damage (3). A favorable correlation between the activity of free radicals (O2, H2O2, OH) in the intestine and the clinical disease activity has been exhibited indicating the significance of these substances in the inflammatory process (4). Effectiveness of various therapies in IBD has been suggested to be related to antioxidant action (5–7). The previous studies showed the existence of oxidative stress in biological fluids such as saliva (8) and plasma (9) of patients with IBD. One of the markers of oxidative stress is increased lipid peroxidation of the cells that is determined by measuring thiobarbituric acid reactive substances (TBARS) (3). Myeloperoxidase (MPO) is an enzyme found in neutrophils and its activity in the colon is linearly related to infiltration of neutrophils. The assessment of MPO activity is well established for quantification of intestinal inflammation (10). In case of inflammatory conditions like IBD, the levels of neutrophils in inflamed tissues, and consequently MPO enzyme, increase. Acetic acid-induced colitis is an easily inducible model of IBD, and the similarity of the inflammatory mediators profile to IBD mentioned that the inflammatory phase bears some resemblance to human intestinal inflammation (11).

Many herbal concoctions are said to be effective in chronic inflammatory conditions. Labiatae are generally known for their various effects such as analgesic and anti-inflammatory activity (12), antioxidant (13), hepatoprotective (14) and hypoglycemic action (15). Zataria multiflora is a plant owned by the Labiatae family that is distributed only in Iran, Pakistan and Afghanistan. It is greatly used for medicinal and condimental purposes in these countries. This plant with the vernacular name of Avishan Shirazi in Iran has several traditional uses such as antiseptic, anesthetic and antispasmodic (16). From these reported activities for this plant and regarding above-mentioned points about IBD, we hypothesized that Z. multiflora may have an effect on IBD. In this study, we attempted to demonstrate the status of oxidative stress by investigating bowel TBARS and MPO activity accompanied by bowel macroscopic and microscopic findings in experimental model of IBD (acetic acid-induced colitis) in mice.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Conclusion
 References
 
Chemicals

2-Thiobarbituric acid (TBA), 1,1,3,3,-tetraethoxypropan, trichloroacetic acid (TCA), n-butanol, hexadecyl trimethyl ammonium bromide (HETAB), EDTA, O-dianisidine hydrochloride, hydrogen peroxide, acetic acid, prednisolone, phosphate buffer, paraffin, hematoxylin and eosin from Merck Chemical Co. (Germany) were used in this study.

Plant Material

Samples of Z. multiflora were collected from Shiraz, Iran, on May 22, 2005. The leaves of the plant were dried in shadow and stored in the Department of Botany of the Research Institute of Forests and Ranglands (TARI), Tehran. A voucher specimen (No. 58416) has been deposited at the Herbarium of TARI.

Preparation of Total Extract

Amount of 86.4 kg of plant powder was wet with a solvent (methanol) in a closed plastic container; then the wet powder put in a percolator and was macerated in 10 liters methanol (100% v/v) for 24 h and, subsequently, the solution was filtered and concentrated in a percolator by 100 drops per min. This procedure was repeated twice and three times with 10 liters methanol (100 and 80% v/v), respectively. The extract was then concentrated under reduced pressure and appropriate temperature and the solvent was distilled in vacuum, and finally, 1.5 kg solid solvent was produced.

Animals

NMRI albino mice weighing between 20 and 30 g were used for the study. Mice were maintained under standard conditions of temperature (23 ± 1°C), relative humidity (55 ± 10%) and 12 h/12 h light/dark cycle, and fed with a standard pellet diet with water ad libitum. They were housed in standard polypropylene cages with wire mesh top. All studies were carried out using six mice in each group. All ethical considerations using animals were considered carefully and the experimental protocol was approved by the Ethics Committee of TUMS.

Induction of Colitis and Treatments

The protocol of the study including doses and duration of treatment, and groups were all designed according to previous studies (10,17). The study comprised of six different groups as follows: normal or untreated mice which did not receive any treatment; control animals, which received 0.1 ml of 6% acetic acid solution (once, intrarectally); Z. multiflora-treated animals, which received 7 days pretreatment with Z. multiflora (400, 600, 900 p.p.m. in drinking water) and 0.1 ml of 6% acetic acid solution; prednisolone-treated group, which received prednisolone (1.14 mg kg–1, for 3 days) and 0.1 ml of 6% solution. Acetic acid was administered intrarectally on 8th day. Drug treatment was continued until 10th day. Prednisolone as standard drug was started on the day of acetic acid treatment and given orally as suspension containing 0.5% of sodium CMC.

For induction of colitis, overnight fasted mice were anesthetized using pentobarbital sodium (55 mg kg–1, i.p.) and then 0.1 ml of 6% acetic acid solution was instilled into the rectum of the mouse. Animals were allowed to hang in air by holding their tails for 1–2 min. This prevented spillage of the solution from the rectum. After 48 h mice were sacrificed by cervical dislocation and dissected open to remove colon. Five centimeters long piece of colon was flushed gently with saline, cut open and scored for inflammation based on the macroscopic features. Tissues were fixed in 10% formalin saline and examined histopathologically. Biochemical evaluation of colon inflammation was done using assay of MPO activity and TBARS concentration.

Assay of Colon Macroscopic Characters

The colon (5 cm long) was scored for macroscopic features using scoring pattern (10,17) given in the Table 1.


View this table:
[in this window]
[in a new window]

  		Table 1. Scoring pattern

 
Assay of Colon Microscopic (Histological) Characters

To process for microscopic studies, 5 µm thick paraffin sections were stained in hematoxylin and eosin. The stained sections were examined for any inflammatory changes like edema, granulated tissues, ulceration or thickening of mucosa, inflammation, existence of polymorphonuclears and mononuclears, necrosis, disrupted architecture of the crypt, and narrow lumen. The sections were all recorded by a histopathologist and a sign score between 0 and 3 for each sign and a total of 24 were used to determine the severity of colon inflammation (10,17).

Assay of Colon MPO Activity

To measure MPO activity, colonic samples were minced on ice and homogenized in 10 ml of ice-cold 50 mM potassium phosphate buffer (pH 6.0), containing 0.5% HETAB and 10 mM EDTA. The homogenates were then sonicated and centrifuged for 20 min at 12 000 g. MPO activity was measured spectrophotometrically as follows: 0.1 ml of supernatant was combined with 2.9 ml of 50 mM phosphate buffer containing 0.167 mg ml–1 O-dianisidine hydrochloride and 0.0005% H2O2. The change in absorbance was measured spectrophotometrically (Shimadzu 160A UV-VIS spectrophotometer) at 460 nm. One unit of MPO activity is defined as the change in absorbance per minute at room temperature, in the final reaction. MPO activity (U g–1) = X/weight of the piece of tissue taken, where X = 10 x change in absorbance per minute/volume of supernatant taken in the final reaction (10).

Assay of Colon TBARS Concentration

Malondialdehyde (MDA) is the main end product of the oxidation of polyunsaturated fatty acids and its concentration in the medium is an established measure of lipid peroxidation extent. In this test, the reaction of TBA with lipid peroxide products makes a complex which is determined spectrophotometrically and lipid peroxidation in samples are assessed in terms of TBARS produced. Briefly, the colonic samples were homogenized in buffered saline (1:5) and then 800 µl of TCA (28% w/v) was added to 400 µl of this mixture and centrifuged in 3000 g for 30 min. Then, 600 µl of the supernatant was added to 150 µl of TBA (1% w/v). Then the mixture was incubated for 15 min in a boiling water bath and then 4 ml n-butanol was added, the solution was centrifuged, cooled and absorption of the supernatant was recorded in 532 nm by UV-160-A Shimadzu double beam spectrophotometer (Japan). The calibration curve of a 1,1,3,3-tetraethoxypropan standard solutions was used to determine the concentrations of TBARS that presented as µmol g–1 of colon (18).

Statistical analysis

Values are reported as mean ± SEM. Statistical significance between groups was computed by analysis of variance (ANOVA) and Tukey multiple comparison post hoc tests. P-values <0.05 were considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Conclusion
 References
 
Significant Macroscopic and Microscopic Changes in the Colon

Colon macroscopic and microscopic changes in control and Z. multiflora-treated groups are shown in Tables 2 and 3, respectively. Intrarectal instillation of acetic acid caused significant inflammatory reactions as indicated by macroscopic and microscopic changes (Tables 2 and 3). Z. multiflora-treated (600 and 900 p.p.m.) and prednisolone-treated groups showed significantly lower score values of macroscopic and microscopic characters when compared with the control group. Positive effects of Z. multiflora (900 p.p.m.) in acetic acid-induced colon macroscopic and microscopic alterations were comparable with that of prednisolone. Histology photographs of the colon sections from different treated groups are shown in Figs 1–6GoGoGoGoGo that match well with macroscopic and microscopic scores (Tables 2 and 3).


View this table:
[in this window]
[in a new window]

  		Table 2. Evaluation based on macroscopic features in acetic acid-induced colitis

 

View this table:
[in this window]
[in a new window]

  		Table 3. Evaluation based on microscopic features in acetic acid-induced colitis

 

Figure 1
View larger version (128K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 1. Light micrograph of bowel tissue from normal or untreated animals which did not receive any treatment. No major histological changes are apparent in micrograph. (H & E, x40 and x100).

 

Figure 2
View larger version (73K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 2. Light micrographs of bowel tissues from control mice received 0.1 ml of 6% acetic acid solution (once, intrarectally). Major histological changes are apparent in micrograph. Ed, edema; TM, thickened mucosa; GT, granulated tissue; In, inflammation; NL, narrowed lumen; Ne, necrosis; DAC, disrupted architecture of the crypt; PMN, polymorphonuclears; MN, mononuclear; FUM, focal ulceration of mucosa (H & E, x& E, x40 and x100).

 

Figure 3
View larger version (91K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 3. Light micrographs of bowel tissues from prednisolone-treated group, which received prednisolone (1.14 mg kg–1 for 3 days) and acetic acid (0.1 ml, 6% solution, once, intrarectally). Minor histological changes are apparent (H & E, x40 and x100).

 

Figure 4
View larger version (95K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 4. Light micrograph of bowel tissue from Z. multiflora-treated animals, which received 7 days pretreatment with extract (400 p.p.m. in drinking water) and 0.1 ml of 6% acetic acid solution. Major histological changes are apparent in micrograph. Ed, edema; GT, granulated tissue; In, inflammation; Ne, necrosis; DAC, disrupted architecture of the crypt; PMN, polymorphonuclears; MN, mononuclear; TM, thickened mucosa (H & E, x40 and x100).

 

Figure 5
View larger version (92K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 5. Light micrograph of bowel tissue from Z. multiflora-treated animals, which received 7 days pretreatment with extract (600 p.p.m. in drinking water) and 0.1 ml of 6% acetic acid solution. Some histological changes are apparent. Ed, edema; In, inflammation; DAC, disrupted architecture of the crypt; NL, narrowed lumen; FUM, focal ulceration of mucosa; GT, granulated tissue (H & E, x40 and x100).

 

Figure 6
View larger version (94K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 6. Light micrograph of bowel tissue from Z. multiflora-treated animals, which received 7 days pretreatment with extract (900 p.p.m. in drinking water) and 0.1 ml of 6% acetic acid solution. Ed, edema; NL, narrowed lumen; DAC, disrupted architecture of the crypt. Minor histological changes are apparent (H & E, x40 and x100).

 
Lipid Peroxidation Revealed Significant Changes

The changes in the extent of lipid peroxidation in bowel homogenate of treated animals is shown in Fig. 7. The TBARS level significantly increased in control group in comparison to normal group (3.14 versus 5.11 µmol g–1 colon). The TBARS level significantly decreased in Z. multiflora-treated (600 and 900 p.p.m.) and prednisolone-treated groups. The mean percentage of decreases of TBARS in Z. multiflora-treated (600 and 900 p.p.m.) and prednisolone-treated groups were 22.71, 32.14 and 31.2, respectively.


Figure 7
View larger version (14K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 7. Effects of Z. multiflora (Z) and prednisolone on lipid peroxidation in acetic acid-induced colitis. Each value represents mean ± SEM percentage of reduction of acetic acid-induced TBARS elevation by treated compounds. The mean ± SEM of TBARS level in normal and control groups were 3.14 ± 0.31 and 5.11 ± 0.50 (µmol g–1 colon), respectively.

 
Colon Myeloperoxidase Activity Changes

The changes in the activity of MPO in bowel homogenates of treated animals is shown in Fig. 8. The MPO activity of control group showed significant increase in comparison to normal group (2.89 versus 4.76 U g–1 colon). The MPO activity decreased in Z. multiflora-treated (600 and 900 p.p.m.) and prednisolone-treated groups compared to control group. The mean percentages of decreases of MPO activity in Z. multiflora-treated (600 and 900 p.p.m.) and prednisolone-treated groups were 24.9, 50, and 48.81, respectively.


Figure 8
View larger version (12K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 8. Effects of Z. multiflora (Z) and prednisolone on MPO activity in acetic acid-induced colitis. Each value represents mean ± SEM percentage of reduction of acetic acid-induced MPO elevation by treated compounds. The mean ± SEM of MPO activity in normal and control groups were 2.89 ± 0.17 and 4.76 ± 0.15 (U g–1 colon), respectively.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Conclusion
 References
 
The results showed that Z. multiflora has a good potential to suppress colitis in mice as indicated by the macroscopic, microscopic and biochemical evaluations. Biochemical assays well indicated that administration of Z. multiflora reduces MPO activity and TBARS concentrations, both of which are established indicators of oxidative stress and markers of colitis (8,11,19). Interestingly, Z. multiflora specially at dose of 900 p.p.m. was comparable with prednisolone which showed significant protection against acetic acid-induced colitis proved by biochemical, macroscopic and microscopic examinations. Acetic acid-induced colitis model in mice is similar to human ulcerative colitis in terms of histological features. It affects the distal colon portion and induces non-transmural inflammation, massive necrosis of mucosal and submucosal layers, mucosal edema, neutrophil infiltration of the mucosa and submucosal ulceration. The protonated form of the acid liberates protons within the intracellular space and causes a massive intracellular acidification resulting in massive epithelial damage. Inflammation is the pathogenesis of IBD and several pathways are associated with inflammatory response in IBD.

The inflammatory response initiated by acetic acid includes activation of cyclooxygenase and lipooxygenase pathways (20,22). Prednisolone as an anti-inflammatory agent decreases the recruitment of macrophages in the affected area and suppresses the synthesis of many inflammatory mediators, e.g. production of IL-1 from monocytes, production of IL-2 and tumor necrosis factor from lymphocytes. Prednisolone also inhibit the enzyme phospholipase A2 and thus decreases availability of prostaglandins and leukotrienes (23). Therefore, the first concept that may come to mind is that Z. multiflora possesses inhibitory effects on the synthesis or release of these inflammatory mediators. Supporting this idea, antinociceptive and anti-inflammatoty effects of the aqueous infusion, ethanolic maceration extract (24,25), the hydroalcoholic extract and the essential oil (26) of the aerial parts of Z. multiflora have been shown and are possibly due to the inhibition of cyclooxygenase enzymes (24). The composition of the essential oil of Z. multiflora was studied by GLC, column chromatography (CC), NMR and GLC/MS (27–30).

Zatarinal, ß-sitosterol, stigmasterol, oleanolic acid, betulic acid, hexadecanoic, luteolin, {alpha}-tocophorolquinone and rosmarinic acid (RA) were reported as the composition of Z. multiflora essential oil. On the other hand, phytochemical screening of ethanolic extract of the plant supported the presence of flavonoids in Z. multiflora (31,32), mainly carvacrol, p-cymene, thymol, linalool and {gamma}-terpinene (29). The luteolin, one of the compositions of Z. multiflora has shown inhibitory effects on TNF-{alpha}-induced IL-8 production in the intestinal epithelial cells. Interleukin IL-8 plays a central role in the initiation and maintenance of inflammatory responses in the IBD (33).

The RA another component of Z. multiflora essential oil has been reported to have antibacterial, antiviral, antioxidant and anti-inflammatory potentials (34–36). RA inhibits the adhesion molecule ICAM-1, which is primarily involved in interactions with ß2 integrins during inflammatory responses, and inhibits the synthesis of eicosanoids, and oxidative DNA injury (36,37). Oxidative stress is believed to play a key role in the pathogenesis of IBD-related intestinal damage (8,9,38–42). As a matter of fact, intestinal mucosal damage in the IBD, including Crohn's disease and ulcerative colitis, is related to both increased free radical production and to a low concentration of endogenous antioxidant defense (43,44). Supporting this idea, the activity of MPO, which is a major enzyme in the formation of reactive oxygen species leading to tissue damage increased in this colitis model. Together with the membranous NADPH oxidase, MPO is involved in the formation of reactive oxygen species and oxidation of biological material. It produces not only oxidative equivalents, but contributes also to the regulation in general response to invading microorganisms (19). Increased TBARS as a marker of lipid peroxidation observed in association with higher MPO activity in this experimental colitis model again confirms the role of free radicals in IBD.

Flavonoids as the main constituent of Z. multiflora extract are a class of plant phenolics with significant antioxidant and chelating properties. Their positive effects come from their ability to inhibit lipid peroxidation, chelate redox-active metals and attenuating other procedure involving reactive oxygen species. From this point of view, there is a great interest in interactions between polyphenolic substance and the intestinal mucosa, including their possible role as modulators of proliferation and apoptosis in the rapidly proliferating cells of the gastrointestinal epithelia (45,46). Recent studies have shown that flavonoids exert a beneficial effect in experimental colon inflammation (47,48). In addition, the anti-inflammatory effects of flavonoids seem to be related to a decrease of neutrophils infiltration, absence of upregulation of IL-1ß and decrease of prostaglandin production in colon mucosa (49). In supporting this idea, there is evidence that flavonoids have anti-phosphodiesterase activity and thus could elevate intracellular levels of cyclic nucleotides (50). Recent studies well indicate that both cAMP and cGMP can diminish oxidative stress in many biological systems and diseases (51–56). Therefore, the beneficial effects of Z. multiflora in IBD mostly back to its strong antioxidant potential.

On the other hand, GC-MS in the absolute of fresh plant showed that thymol is the major constituent while carvacrol is the major constituent in the absolute of dried plant (57). The Z. multiflora oil exhibited strong antimicrobial activity against Escherichia coli, Staphylococcus aureus and Salmonella typhimurium (58–60). In addition, both thymol and carvacrol in Z. multiflora essential oil exerted antibacterial and antifungal effects (61). Thus, antimicrobial activity of Z. multiflora can be another mechanism of action for its beneficial effects in IBD.


   Conclusion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
References
 
Taking collectively, the data provide very good evidence on benefit of Z. multiflora in experimental model of IBD. This effect supports the antioxidant, antimicrobial and anti-inflammatory potentials of Z. multiflora. Regarding the resemblance of acetic acid-induced colitis to human UC (62), it can be concluded that Z. multiflora extract may be useful in treating UC in humans. Proper clinical investigations should also be carried out to confirm the same activity in human disease. It should not be forgotten that there are a lot of herbal formulas in the Asia and Middle East regions that are used traditionally. However, little effort has been made so far to scientifically clarify the nature of such effects. Scientists from these regions of the world are responsible for confirming the pharmacological effects of these herbals by suitable animal tests. Many of them are capable entering clinical trials and deserve to be used as a drug in humans with minor adverse effects in comparison to synthetic compounds (63,64).


  Footnotes
 
For reprints and all correspondence: Mohammad Abdollahi, Laboratory of Toxicology, Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Poursina Avenue, Tehran University, Tehran 14155-6451, Iran. Tel/Fax: +98-21-6959104; E-mail: mohammad.abdollahi{at}utoronto.ca/ mohammad{at}tums.ac.ir


   Acknowledgments
 
This study was carried out with financial support from Research Council of Tehran University of Medical Sciences.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Conclusion
 References
 

  1. Simmonds NJ and Rampton DS. ( 1993;) Inflammatory bowel disease—a radical view. Gut 34:: 865–8.[Free Full Text]
  2. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, et al. ( 1996;) Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 41:: 2078–86.[CrossRef][Web of Science][Medline]
  3. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaiee A. ( 2004;) Pesticides and oxidative stress: a review. Med Sci Monit 10:: RA144–7.
  4. Nielsen OH and Ahnfelt-Ronne I. ( 1991;) Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease. Klin Wochenschr 69:: 995–1000.[CrossRef][Web of Science][Medline]
  5. Barbosa DS, Cecchini REl, Kadri MZ, Rodriguez MA, Burini RC, Dichi I. ( 2003;) Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19:: 837–42.[CrossRef][Web of Science][Medline]
  6. Hirayama A, Nagase S, Ueda A, Ishizu T, Taru Y, Yoh K, et al. ( 2003;) Oxidative stress during leukocyte absorption apheresis. J Clin Apher 18:: 61–6.[CrossRef][Web of Science][Medline]
  7. Ahnfelt-Ronne I and Nielsen OH. ( 1987;) The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents Actions 21:: 191–4.[CrossRef][Web of Science][Medline]
  8. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. ( 2004;) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49:: 1752–7.[CrossRef][Web of Science][Medline]
  9. D'Odorico A, Bortolan S, Cardin R, D'Inca' R, Martines D, Ferronato A, et al. ( 2001;) Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 36:: 1289–94.[CrossRef][Web of Science][Medline]
  10. Krawisz JE, Sharon P, Stenson WF. ( 1984;) Qualitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:: 1344–50.[Web of Science][Medline]
  11. Elson CO, Sartor RB, Tennyson GS, Riddell RH. ( 1995;) Experimental models of inflammatory bowel disease. Gastroenterology 109:: 1344–67.[CrossRef][Web of Science][Medline]
  12. Hernandez-Perez M, Rabanal RM, de la Torre MC, Rodriguez B. ( 1995;) Analgesic, anti-inflammatory, antipyretic and haematological effects of aethiopinone, an o-naphthoquinone diterpenoid from Salvia aethiopis roots and two hemisynthetic derivatives. Planta Med 61:: 505–9.[Web of Science][Medline]
  13. Cuppett SL and Hall CA 3rd. ( 1998;) Antioxidant activity of the Labiatae. Adv Food Nutr Res 42:: 245–71.[Medline]
  14. Wasser S, Ho JM, Ang HK, Tan CE. ( 1998;) Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. J Hepatol 29:: 760–71.[CrossRef][Web of Science][Medline]
  15. Hosseinzadeh H, Haddad Khodaparast MH, Shokohizadeh H. ( 1998;) Antihyperglycemic effect of Saliva leriifolia leaf and seed extract in mice. Irn J Med Sci 23:: 78–80.
  16. Zargari A. ( 1990;) Medicinal Plants 4th edn (Tehran University Press, Tehran) pp. 1–57.
  17. Jagtap AG, Shirke SS, Phadke AS. ( 2004;) Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 90:: 195–204.[CrossRef][Web of Science][Medline]
  18. Satho K. ( 1978;) Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin Chem Acta 90:: 37–43.[CrossRef][Web of Science][Medline]
  19. Arnhold J. ( 2004;) Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Mosc) 69:: 4–9.[CrossRef][Medline]
  20. Sharon P and Stenson WF. ( 1985;) Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenteroloogy 88:: 55–63.
  21. Elson CO, Cong Y, Brandwein S, Weaver CT, McCabe RP, Mahler M, et al. ( 1998;) Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann N Y Acad Sci 859:: 85–95.[CrossRef][Web of Science][Medline]
  22. MacPherson B and Pfeiffer CJ. ( 1976;) Experimental colitis. Digestion 14:: 424–52.[Web of Science][Medline]
  23. Katzung BG. ( 2000;) Basic & Clinical Pharmacology 8th edn New York. Appleton & Lange.
  24. Hosseinzadeh H, Ramezani M, Salmani GA. ( 2000;) Antinociceptive, anti-inflammatory and acute toxicity effects of Zataria multiflora Boiss extracts in mice and rats. J Ethnopharmacol 73:: 379–85.[CrossRef][Web of Science][Medline]
  25. Ramezani M, Hosseinzadeh H, Samizadeh S. ( 2004;) Antinociceptive effects of Zataria multiflora Boiss fractions in mice. J Ethnopharmacol 91:: 167–70.[CrossRef][Web of Science][Medline]
  26. Jaffary F, Ghannadi A, Siahpoush A. ( 2004;) Antinociceptive effects of hydroalcoholic extract and essential oil of Zataria multiflora. Fitoterapia 75:: 217–20.[CrossRef][Web of Science][Medline]
  27. Shafiee A and Javidnia K. ( 1997;) Composition of essential oil of Zataria multiflora. Planta Med 63:: 371–2.[CrossRef][Web of Science][Medline]
  28. Ebrahimzadeh H, Yamini Y, Sefidkon F, Chaloosi M, Pourmortazavi SM. ( 2003;) Chemical composition of the essential oil and supercritical CO2 extracts of Zataria multiflora Boiss. Food Chem 83:: 357–61.
  29. Mohagheghzadeh A, Shams-Ardakani M, Ghannadi A. ( 2000;) Volatile constituents of callus and flower-bearing tops of Zataria multiflora Boiss (Lamiaceae). Flavour Fragr J 15:: 373–6.
  30. Shaiq Ali M, Jahangir M, Saleem M, Uddin Ahmad V. ( 1999;) Chemical constituents of Pulicaria gnaphalodes. Nat Prod Sci 5:: 134–7.
  31. Martinez-Vazquez M, Ramirez Apan TO, Aguilar H, Bye R. ( 1996;) Analgesic and antipyretic activities of an aqueous extract and of the flavone linarin of Buddleia cordata. Planta Med 62:: 137–40.[Web of Science][Medline]
  32. Ramesh M, Rao YN, Rao AV, Prabhakar MC, Rao CS, Muralidhar N, et al. ( 1998;) Antinociceptive and anti-inflammatory activity of a flavonoid isolated from Caralluma attenuata. J Ethnopharmacol 62:: 63–6.[CrossRef][Web of Science][Medline]
  33. Kim JA, Kim DK, Kang OH, Choi YA, Park HJ, Choi SC, et al. ( 2005;) Inhibitory effect of luteolin on TNF-alpha-induced IL-8 production in human colon epithelial cells. Int Immunopharmacol 5:: 209–17.[CrossRef][Web of Science][Medline]
  34. Parnham MJ and Kesselring K. ( 1985;) Rosmarinic acid. Drugs Future 10:: 756–7.
  35. Mohagheghzadeh A, Shams-Ardakani M, Ghannadi A, Minaeian M. ( 2004;) Rosmarinic acid from Zataria multiflora tops and in vitro cultures. Fitoterapia 75:: 315–21.[CrossRef][Web of Science][Medline]
  36. Osakabe N, Yasuda A, Natsume M, Yoshikawa T. ( 2004;) Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model. Carcinogenesis 25:: 549–57.[Abstract/Free Full Text]
  37. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. ( 1988;) Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 52:: 925–33.[CrossRef][Web of Science][Medline]
  38. Tuzun A, Erdil A, Inal V, Aydin A, Bagci S, Yesilova Z, et al. ( 2002;) Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 35:: 569–72.[CrossRef][Web of Science][Medline]
  39. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. ( 1996;) Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 98:: 136–41.[Web of Science][Medline]
  40. Grisham MB. ( 1994;) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:: 859–61.[CrossRef][Web of Science][Medline]
  41. Allgayer H. ( 1991;) Clinical relevance of oxygen radicals in inflammatory bowel disease—facts and fashion. Klin Wochenschr 69:: 1001–3.[CrossRef][Web of Science][Medline]
  42. Grisham MB and Granger DN. ( 1988;) Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 33:: 6S–15S.[CrossRef][Medline]
  43. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. ( 2004;) Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 49:: 1433–7.[CrossRef][Web of Science][Medline]
  44. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, et al. ( 2003;) Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 201:: 17–27.[CrossRef][Web of Science][Medline]
  45. Le Marchand L. ( 2002;) Cancer preventive effects of flavonoids—a review. Biomed Pharmacother 56:: 296–301.[CrossRef][Medline]
  46. Setchell KD and Cassidy A. ( 1999;) Dietary isoflavones: biological effects and relevance to human health. J Nutr 129:: 758S–67S.
  47. Sanchez de Medina F, Vera B, Galvez J, Zarzuelo A. ( 2002;) Effect of quercitrin on the early stages of hapten induced colonic inflammation in the rat. Life Sci 70:: 3097–108.[CrossRef][Web of Science][Medline]
  48. Hong T, Jin GB, Cho S, Cyong JC. ( 2002;) Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med 68:: 268–71.[CrossRef][Web of Science][Medline]
  49. Villegas I, Alarcon de la Lastra C, Orjales A, La Casa C. ( 2003;) A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice. Int Immunopharmacol l3:: 1731–41.[CrossRef][Web of Science][Medline]
  50. Abdollahi M, Chan TS, Subrahmanyam V, O'Brien PJ. ( 2003;) Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 252:: 205–11.[CrossRef][Web of Science][Medline]
  51. Abdollahi M, Bahreini-Moghadam A, Emami B, Fooladian F, Zafari K. ( 2003;) Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp Biochem Physiol C Toxicol Pharmacol 135:: 331–6.
  52. Abdollahi M, Fooladian F, Emami B, Zafari K, Bahreini-Moghadam A. ( 2003;) Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol 22:: 587–92.[Abstract/Free Full Text]
  53. Aghababaeian R, Ghazi-Khansari M, Abdi K, Taghadosinejad F, Abdollahi M. ( 2005;) Protective effects of sildenafil and dipyridamol from lead-induced lipid peroxidation in perfused rat liver. Intl J Pharmacol 1:: 157–60.
  54. Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M. ( 2005;) Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 140:: 251–5.[CrossRef][Web of Science][Medline]
  55. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. ( 2005;) Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 59:: 302–6.[CrossRef][Medline]
  56. Zamani MJ, Sharifzadeh M, Rezaie A, Mashayekhi F, Abdollahi M. ( 2005;) Effects of sildenafil on rat irritable bowel syndrome. Therapy 2:: 237–42.
  57. Saleem M, Nazli R, Afza N, Sami A, Ali MS. ( 2004;) Biological significance of essential oil of Zataria multiflora boiss. Nat Prod Res 18:: 493–7.[CrossRef][Web of Science][Medline]
  58. Rasooli I and Rezaei MB. ( 2002;) Bioactivity and chemical properties of essential oils from Zataria multiflora Boiss and Mentha longifolia (L.) Huds. J Essent Oil Res 14:: 141–6.
  59. Basti AA, Razavilar V, Misaghi A, Radmehr B, Abbasifar R, Yazdani D, et al. ( 2004;) Effect of Zataria multiflora Boiss. essential oil on probability of growth initiation of Staphylococcus aureus in a brain heart infusion broth. J Med Plants 3:: 53–60.
  60. Basti AA, Razavilar V, Abbasifar R, Radmehr B, Misaghi A, Khalighi Sigaroodi F. ( 2004;) Effect of Zataria multiflora Boiss essential oil on probability of growth initiation of Salmonella typhimurium in a brain heart infusion broth. J Med Plants 3:: 85–92.
  61. Shafiee A, Javidnia K, Tabatabai M. ( 1999;) Volatile constituents and antimicrobial activity of Zataria multiflora, population Iran. Irn J Chem Chem Eng 18:: 1–5.
  62. Jurjus AR, Khoury NN, Reimund JM. ( 2004;) Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 50:: 81–92.[Medline]
  63. Kiyohara H, Matsumoto T, Yamada H. ( 2004;) Combination effects of herbs in a multi-herbal formula: expression of Juzen-taiho-to's immuno-modulatory activity on the intestinal immune system. Evid Based Complement Alternat Med 1:: 83–91.[Abstract/Free Full Text]
  64. Hadjibabaie M, Rastkari N, Rezaie A, Abdollahi M. ( 2005;) The adverse drug reaction in the gastrointestinal tract: an overview. Intl J Pharmacol 1:: 1–8.
Received January 10, 2006; accepted June 19, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
T.-C. Lu, J.-C. Liao, T.-H. Huang, Y.-C. Lin, C.-Y. Liu, Y.-j. Chiu, and W.-H. Peng
Analgesic and Anti-Inflammatory Activities of the Methanol Extract from Pogostemon cablin
Evid. Based Complement. Altern. Med., November 20, 2009; (2009) nep183v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Dabek, L. Ferrier, R. Roka, K. Gecse, A. Annahazi, J. Moreau, J. Escourrou, C. Cartier, G. Chaumaz, M. Leveque, et al.
Luminal Cathepsin G and Protease-Activated Receptor 4: A Duet Involved in Alterations of the Colonic Epithelial Barrier in Ulcerative Colitis
Am. J. Pathol., July 1, 2009; 175(1): 207 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, and R. Gambari
Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of {beta}-Thalassemia and Sickle-Cell Anemia
Evid. Based Complement. Altern. Med., June 1, 2009; 6(2): 141 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
H.-Y. Chang, M.-J. Sheu, C.-H. Yang, T.-C. Lu, Y. S. Chang, W.-H. Peng, S.-S. Huang, and G.-J. Huang
Analgesic Effects and the Mechanisms of Anti-Inflammation of Hispolon in Mice
Evid. Based Complement. Altern. Med., April 6, 2009; (2009) nep027v1.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
4/1/43    most recent
nel051v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nakhai, L. A.
Right arrow Articles by Abdollahi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakhai, L. A.
Right arrow Articles by Abdollahi, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?